Search company, investor...



Unattributed - II | Alive

Total Raised


Last Raised

$3.3M | 2 yrs ago

About Polyphor

Polyphor is a clinical-stage Swiss specialty pharma company focused on the development of macrocycle drugs addressing antibiotic resistance and respiratory diseases. The company's lead drug candidates include Murepavadin (POL7080), a precision Outer Membrane Protein Targeting Antibiotic (OMPTA) against Pseudomonas aeruginosa; POL6014, an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases; and Balixafortide (POL6326), an antagonist of the chemokine receptor CXCR4 for combination treatment in oncology. Polyphor has discovered the OMPTA class and is further developing it, including broad-spectrum preclinical candidates, to address infections caused by difficult-to-treat, resistant Gram-negative pathogens - one of the most pressing emerging medical needs. In addition, Polyphor has substantial technology partnerships with its Discovery business unit to assist pharma clients in research programs addressing difficult targets through its proprietary macrocycle technology platform.

Headquarters Location

Hegenheimermattweg 125

Allschwil, CH-4123,


+41 61 567 16 00

Missing: Polyphor's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Polyphor's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Polyphor

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Polyphor is included in 2 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Polyphor Patents

Polyphor has filed 1 patent.

The 3 most popular patent topics include:

  • Peptides
  • Enterobacteriaceae
  • Muscarinic antagonists
patents chart

Application Date

Grant Date


Related Topics




Proteinogenic amino acids, Amino acids, Peptides, Glucogenic amino acids, Cyclo-cross cyclists


Application Date


Grant Date



Related Topics

Proteinogenic amino acids, Amino acids, Peptides, Glucogenic amino acids, Cyclo-cross cyclists



Latest Polyphor News

Spexis to present at BIO-Europe® 2022

Oct 18, 2022

Spexis AG (SIX: SPEX) today announced that the company will present and participate in one-on-one meetings at BIO-Europe® , taking place October 24-26, 2022 in Leipzig, Germany, and virtually, November 2-4, 2022. Jeff Wager, CEO of Spexis, will provide an overview of the company and its pipeline. The in-person presentation will be on Tuesday, October 25th from 13:30 to 13:45 CEST in Multi-purpose Room 4. Jeff Wager and Stephan Wehselau, COO, will both be available to participate in one-on-one meetings. To schedule a meeting with the company, please use PartneringONE® , the conference partnering system. For Investors:   U.S.: +1 339 832 0752     About Spexis Spexis AG (SIX:SPEX) is a clinical-stage, publicly listed biopharmaceutical company. The company is focused on discovering and developing first-in-class macrocyclic molecules for rare diseases and cancers. The most advanced of four clinical candidates is ColiFin®, an inhaled therapeutic for cystic fibrosis. ColiFin® is already approved and marketed in Europe and is planned to enter global pivotal Phase 3 testing in early 2023 subject to financing. Furthermore, Spexis is applying its leading macrocyclic technology platform, the result of more than 25 years and $400 million of cumulative research and investment, to discover promising therapeutic candidates that can target difficult-to-drug structures. With a pipeline of potentially transformative product candidates, Spexis aims to deliver substantial benefits to patients and meaningful value to society and its stakeholders. For further information, please visit: . Disclaimer This press release contains forward-looking statements which are based on current assumptions and forecasts of Spexis management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Spexis' results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only as of the date of this communication. Spexis disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise. End of Media Release

Polyphor Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Polyphor Rank

Polyphor Frequently Asked Questions (FAQ)

  • Where is Polyphor's headquarters?

    Polyphor's headquarters is located at Hegenheimermattweg 125, Allschwil.

  • What is Polyphor's latest funding round?

    Polyphor's latest funding round is Unattributed - II.

  • How much did Polyphor raise?

    Polyphor raised a total of $43.09M.

  • Who are the investors of Polyphor?

    Investors of Polyphor include Cystic Fibrosis Foundation, CARB-X, Novo Holdings, Wellcome Trust and Novartis Venture Funds.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.